• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form S-1/A filed by HWH International Inc.

    10/23/24 5:27:13 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care
    Get the next $HWH alert in real time by email
    S-1/A 1 forms-1a.htm

     

    As filed with the Securities and Exchange Commission on October 23, 2024

     

    Registration No. 333-282567

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    Amendment No. 1 to

    Form S-1

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    HWH International Inc.
    (Exact Name of Registrant as Specified in its Charter)

     

    Delaware   5122   87-3296100

    (State or other jurisdiction of

    incorporation or organization)

     

    (Primary Standard Industrial

    Classification Code Number)

     

    (I.R.S. Employer

    Identification No.)

     

    4800 Montgomery Lane, Suite 210

    Bethesda, MD

    1-301-971-3955

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    John Thatch

    Chief Executive Officer

    HWH International Inc.

    4800 Montgomery Lane, Suite 210

    Bethesda, MD 20814

    1-301-971-3955

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Darrin M. Ocasio, Esq.

    Sichenzia Ross Ference Carmel LLP

    1185 Avenue of the Americas, 31st Floor

    New York, NY 10036

    Telephone: (212) 930-9700

     

    Joseph M. Lucosky, Esq.

    Lucosky Brookman LLP
    101 Wood Avenue South, 5th Floor

    Woodbridge, NJ 08830

    Tel: (732) 395-4400

    Fax: (732) 395-4401

     

    Approximate date of commencement of proposed sale to the public: As soon as practicable after this registration statement is declared effective.

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the following box. ☐

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
        Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended (the “Securities Act”), or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Amendment to the Registration Statement on Form S-1 (File No. 333-282567) is filed solely to amend Item 16 of Part II thereof in order to update certain exhibits thereto. This Amendment does not modify any provision of the preliminary prospectus contained in Part I. Accordingly, the preliminary prospectus has been omitted.

     

     

     

     

    PART II:

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    We have filed the exhibits listed on the accompanying exhibit index of this registration statement.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
         
    1.1*   Form of Underwriting Agreement
    1.2   Underwriting Agreement, incorporated by reference to Exhibit 1.1 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022
    2.1   Merger Agreement dated September 9, 2022 by and among Alset Capital Acquisition Corp., HWH Merger Sub, Inc. and HWH International Inc., incorporated by reference to Exhibit 2.1 to Form 8-K filed with the SEC on September 12, 2022.
    3.1   Amended and Restated Certificate of Incorporation dated February 2, 2022, incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022.
    3.2   By Laws, incorporated by reference to Exhibit 3.3 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    3.3   Amendment to the Amended and Restated Certificate of Incorporation of Alset Capital Acquisition Corp., dated May 2, 2023, incorporated by reference to Exhibit 3.1 of the registrant’s current report on Form 8-K filed with the SEC on May 3, 2023.
    3.4   Amendment to Certificate of Incorporation, incorporated by reference to the registrant’s current report on Form 8-K filed with the SEC on November 3, 2023.
    4.1   Specimen Unit Certificate, incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022
    4.2   Specimen Class A Common Stock Certificate, incorporated by reference to Exhibit 4.2 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022
    4.3   Specimen Warrant Certificate, incorporated by reference to Exhibit 4.3 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022
    4.4   Specimen Right Certificate, incorporated by reference to Exhibit 4.4 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022
    4.5   Warrant Agreement between Vstock Transfer LLC and the Registrant, incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022
    4.6   Rights Agreement between Vstock Transfer LLC and the Registrant, incorporated by reference to Exhibit 4.2 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022
    4.7   Form of Pre-funded Warrant
    5.1*   Opinion of Sichenzia Ross Ference Carmel LLP
    10.1   Letter Agreement among the Registrant and our officers, directors and Alset Management Group, Inc., incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022.
    10.2   Promissory Note, dated November 8, 2021, issued to Alset Acquisition Sponsor LLC, incorporated by reference to Exhibit 10.2 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    10.3   Investment Management Trust Agreement between Wilmington Trust Company and the Registrant, incorporated by reference to Exhibit 10.2 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022.
    10.4   Registration Rights Agreement between the Registrant and certain security holders, incorporated by reference to Exhibit 10.3 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022.
    10.5   Securities Subscription Agreement, dated November 8, 2021, between the Registrant and Alset Acquisition Sponsor LLC, incorporated by reference to Exhibit 10.5 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    10.6   Placement Unit Purchase Agreement between the Registrant and Alset Acquisition Sponsor, LLC, incorporated by reference to Exhibit 10.4 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022.
    10.7   Form of Indemnity Agreement, incorporated by reference to Exhibit 10.7 of the Registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    10.8   Administrative Support Agreement by and between the Registrant and Alset Management Group, Inc., incorporated by reference to Exhibit 10.6 of the Registrant’s Current Report on Form 8-K/A filed with the SEC on February 8, 2022
    10.9   Sponsor Support Agreement dated as of September 9, 2022, by and among Alset Capital Acquisition Corp. and each of the Persons set forth on Schedule I attached thereto, incorporated by reference to Exhibit 10.1 to Form 8-K filed with the SEC on September 12, 2022.
    10.10   Shareholder Support Agreement dated as of September 9, 2022, by and among Alset Capital Acquisition Corp., HWH International Inc. and each of the Persons set forth on Schedule I attached thereto, incorporated by reference to Exhibit 10.2 to Form 8-K filed with the SEC on September 12, 2022.
    10.11   Amendment No. 1 to Investment Management Trust Agreement, incorporated by reference to Exhibit 10.1 of the registrant’s current report on Form 8-K filed with the SEC on May 3, 2023.
    10.12   Form of Forward Share Purchase Agreement, dated July 30, 2023, incorporated by reference to Exhibit 10.1 of the registrant’s current report on Form 8-K filed with the SEC on July 31, 2023.
    10.13   Form of FPA Funding Amount PIPE Subscription Agreement, dated July 30, 2023, incorporated by reference to Exhibit 10.2 of the registrant’s current report on Form 8-K filed with the SEC on July 31, 2023.
    10.14   Amendment No. 2 to Investment Management Trust Agreement, incorporated by reference to Exhibit 10.1 of the registrant’s current report on Form 8-K filed with the SEC on November 3, 2023.
    10.15   Satisfaction and Discharge Agreement, dated December 18, 2023, incorporated by reference to Exhibit 10.3 of the registrant’s current report on Form 8-K filed with the SEC on January 12, 2024.
    10.16   Credit Facility Agreement between Alset Inc. and HWH International Inc., dated April 24, 2024, incorporated by reference to exhibit 10.1 of the registrant’s current report on Form 8-K filed with the SEC on April 25, 2024.
    10.17   Debt Conversion Agreement, between HWH International Inc. and Alset Inc., dated September 24, 2024, incorporated by reference to exhibit 10.1 of the registrant’s current report on Form 8-K filed with the SEC on September 25, 2024.
    10.18   Debt Conversion Agreement, between HWH International Inc. and Alset International Limited, dated September 24, 2024, incorporated by reference to exhibit 10.2 of the registrant’s current report on Form 8-K filed with the SEC on September 25, 2024.
    21   Subsidiaries of the Company, incorporated by reference to Exhibit 21 of the registrant’s annual report on Form 10-K filed with the SEC on February 28, 2024.
    23.1   Auditor Consent of MaloneBailey, LLP., independent registered public accounting firm, incorporated by reference to the Company’s registration statement on Form S-1 (File No. 333-282567), filed on October 10, 2024.
    23.2   Auditor Consent of Grassi & Co., CPAs, P.C., independent registered public accounting firm incorporated by reference to the Company’s registration statement on Form S-1 (File No. 333-282567), filed on October 10, 2024.
    23.3*   Consent of Sichenzia Ross Ference Carmel LLP (included in Exhibit 5.1).
    24.1   Power of Attorney (included on signature page of Registration Statement).
    99.1   Audit Committee Charter, incorporated by reference to Exhibit 99.1 of the registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    99.2   Compensation Committee Charter, incorporated by reference to Exhibit 99.2 of the registrant’s Registration Statement on Form S-1 filed with the SEC on January 13, 2022.
    107*   Filing Fee Table

     

    * Filed herewith.

    ** To be filed by Amendment.

     

    Financial statement schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto.

     

    II-1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Bethesda, State of Maryland, on the 23rd day of October, 2024.

     

    HWH International Inc.  
         
    By: /s/ Rongguo (Ronald) Wei  
    Name: Rongguo (Ronald) Wei  
    Title: Chief Financial Officer  

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints John Thatch and Rongguo (Ronald) Wei, and each one of them, as their true and lawful attorney-in-fact and agent with full power of substitution, for him/her in any and all as their true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for them and in their name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to sign any registration statement for the same offering covered by this registration statement that is to be effective on filing pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and all post-effective amendments thereto, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as they might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ John Thatch   Chief Executive Officer   October 23, 2024
    John Thatch   (Principal Executive Officer)    
             
    /s/ Rongguo (Ronald) Wei   Chief Financial Officer   October 23, 2024
    Rongguo (Ronald) Wei  

    (Principal Financial Officer and

    Principal Accounting Officer)

       
             
    /s/ Wong Shui Yeung (Frankie)   Director   October 23, 2024
    Wong Shui Yeung (Frankie)        
             
    /s/ William Wu   Director   October 23, 2024
    William Wu        
             
    /s/ Wong Tat Keung (Aston)   Director   October 23, 2024
    Wong Tat Keung (Aston)        
             
    /s/ Heng Fai Ambrose Chan   Director   October 23, 2024
    Heng Fai Ambrose Chan        

     

    II-2

     

    Get the next $HWH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HWH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $HWH
    SEC Filings

    View All

    SEC Form 144 filed by HWH International Inc.

    144 - HWH International Inc. (0001897245) (Subject)

    2/11/26 7:37:45 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    HWH International Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - HWH International Inc. (0001897245) (Filer)

    2/5/26 8:45:59 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by HWH International Inc.

    SCHEDULE 13D/A - HWH International Inc. (0001897245) (Subject)

    12/1/25 5:17:55 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HWH International Inc. Announces Reverse Stock Split

    BETHESDA, MD, Feb. 20, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced a 1-for-5 reverse stock split of the Company's common stock to become effective at 9:00 a.m. (Eastern Time) on February 24, 2025. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on February 24, 2025, under the existing trading symbol "HWH." The reverse stock split is primarily intended to bring the Company into compliance with the minimum bid price requirements for maintaining its listing on the Nasdaq Capital Market. The new CUSIP number following the reverse stock split will be 448

    2/20/25 8:50:00 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    D. Boral Capital Served as Placement Agent to HWH International Inc. (Nasdaq: HWH) in connection with its approximately $1.76 Million Public Offering

    BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,900, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,412,500 shares of common stock and 1,000,000 pre-funded warrants to purchase 1,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded

    1/7/25 11:18:56 AM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    HWH International Inc. Announces Closing of Approximately $1.76 Million Public Offering at $0.40 per Share

    BETHESDA, MD, Jan. 06, 2025 (GLOBE NEWSWIRE) -- HWH International Inc. (the "Company") (NASDAQ:HWH), a purpose-driven lifestyle company, today announced the closing of its public offering (the "Offering") with aggregate gross proceeds to the Company of $1,764,875, prior to deducting fees and other expenses payable by the Company. The Offering consisted of 3,125,000 shares of common stock and 1,250,000 pre-funded warrants to purchase 1,250,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) was sold at a purchase price of $0.40 per share (or $0.3999 per pre-funded warrant after reducing $0.0001 attributable to the exercise price of the pre-funded w

    1/6/25 4:20:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    1/20/26 4:59:26 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Chan Heng Fai Ambrose was granted 1,000,000 shares, increasing direct ownership by 38,462% to 1,002,600 units (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    12/1/25 5:10:23 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Large owner Chan Heng Fai Ambrose

    4 - HWH International Inc. (0001897245) (Reporting)

    10/7/25 5:00:04 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Chan Heng Fai Ambrose bought $585,000 worth of shares (1,300,000 units at $0.45) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    12/26/24 5:15:05 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Director Chan Heng Fai Ambrose bought $3,000,000 worth of shares (4,411,764 units at $0.68) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    11/26/24 7:12:12 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Chief Executive Officer Chan Heng Fai Ambrose bought $3,801,758 worth of shares (6,034,537 units at $0.63) (SEC Form 4)

    4 - HWH International Inc. (0001897245) (Issuer)

    9/26/24 9:39:51 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Financials

    Live finance-specific insights

    View All

    HWH International Inc. Acquires Café in South Korea, Unveiling Second Hapi Cafe Outlet

    Bethesda, MD, Feb. 26, 2024 (GLOBE NEWSWIRE) -- HWH International Inc. ("HWH") (NASDAQ:HWH) proudly announces the acquisition of a café in Seocho-gu, South Korea, marking the launch of its second Hapi Cafe outlet in South Korea. HWH is delighted to reveal its latest acquisition of a café nestled in the heart of Seocho-gu, South Korea. This strategic move signifies HWH's dedication to providing unique and welcoming spaces where people can gather to savor food, coffee, and experiences. These cafes are a significant driver of our Health, Wealth, and Happiness vision to offer delicious and nutritious food and beverages to our customers and provide a platform where we can roll out lifestyle pr

    2/26/24 4:15:00 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    $HWH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/26/24 7:34:11 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13D/A filed by HWH International Inc.

    SC 13D/A - HWH International Inc. (0001897245) (Subject)

    11/22/24 5:00:10 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care

    Amendment: SEC Form SC 13G/A filed by HWH International Inc.

    SC 13G/A - HWH International Inc. (0001897245) (Subject)

    11/14/24 12:40:52 PM ET
    $HWH
    Other Pharmaceuticals
    Health Care